These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 6289026

  • 1. Naltrexone, opiate addiction, and endorphins.
    Gold MS, Dackis CA, Pottash AL, Sternbach HH, Annitto WJ, Martin D, Dackis MP.
    Med Res Rev; 1982; 2(3):211-46. PubMed ID: 6289026
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Neuroanatomical sites of action of clonidine in opiate withdrawal: the locus coeruleus connection.
    Gold MS, Pottash AC, Extein IL, Kleber HD.
    Prog Clin Biol Res; 1981; 71():285-98. PubMed ID: 6276897
    [No Abstract] [Full Text] [Related]

  • 6. Naltrexone for opioid addiction.
    Med Lett Drugs Ther; 1985 Feb 01; 27(680):11-2. PubMed ID: 3969057
    [No Abstract] [Full Text] [Related]

  • 7. The role of narcotic antagonists in the rehabilitation of opiate addicts: a review of naltrexone.
    Schecter A.
    Am J Drug Alcohol Abuse; 1980 Feb 01; 7(1):1-18. PubMed ID: 6254356
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Action of naloxone and naltrexone in different types of psychoses.
    Volavka J.
    Mod Probl Pharmacopsychiatry; 1981 Feb 01; 17():202-12. PubMed ID: 6276726
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Naltrexone: a short-term treatment for opiate dependence.
    Greenstein RA, O'Brien CP, McLellan AT, Woody GE, Grabowski J, Long M, Coyle-Perkins G, Vittor A.
    Am J Drug Alcohol Abuse; 1981 Feb 01; 8(3):291-300. PubMed ID: 7340503
    [Abstract] [Full Text] [Related]

  • 16. The role of the National Institute on Drug Abuse in the development of naltrexone.
    Ginzburg HM, Glass WJ.
    J Clin Psychiatry; 1984 Sep 01; 45(9 Pt 2):4-6. PubMed ID: 6088469
    [Abstract] [Full Text] [Related]

  • 17. [Opioid peptides and their receptors].
    Giros B, Schwartz JC.
    Rev Prat; 1987 May 21; 37(29):1695-8, 1701-2. PubMed ID: 3035700
    [No Abstract] [Full Text] [Related]

  • 18. Withdrawal from endogenous opiates.
    Julius DA.
    Am J Psychiatry; 1979 Mar 21; 136(3):358-9. PubMed ID: 420348
    [No Abstract] [Full Text] [Related]

  • 19. Strategies to improve compliance with narcotic antagonists.
    Kosten TR, Kleber HD.
    Am J Drug Alcohol Abuse; 1984 Mar 21; 10(2):249-66. PubMed ID: 6475891
    [Abstract] [Full Text] [Related]

  • 20. Naltrexone reduces weight gain, alters "beta-endorphin", and reduces insulin output from pancreatic islets of genetically obese mice.
    Recant L, Voyles NR, Luciano M, Pert CB.
    Peptides; 1980 Mar 21; 1(4):309-13. PubMed ID: 6272240
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.